RP2 / RP2 + nivolumab
Various Solid Tumors
Key Facts
About Replimune
Founded in 2015, Replimune is at the forefront of developing next-generation oncolytic immunotherapies with the mission to revolutionize cancer treatment. Its lead candidate, RP1 (vusolimogene odeparepvec), has a PDUFA date of July 22, 2025, for advanced melanoma and is being studied across multiple skin cancers. The company's wholly-owned RPx platform and in-house manufacturing capability position it to develop a broad portfolio of treatments aimed at overcoming resistance to current immunotherapies.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Individualized mRNA Cancer Immunotherapies | BioNTech | Phase 2/3 |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved |
| IMA30X Series (ACTengine®) | Immatics | Pre-clinical |
| Bicycle Toxin Conjugates (BTCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Bicycle Radio Conjugates (BRCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Micvotabart pelidotin (MICVO) | Pyxis Oncology | Phase 1 |
| OST-tADC Platform | OS Therapies | Pre-clinical |